Andrea Lobo,  —

Andrea Lobo is a Science writer at BioNews. She holds a Biology degree and a PhD in Cell Biology/Neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. She was a postdoctoral and senior researcher at the Institute for Research and Innovation in Health in Porto, in drug addiction, studying neuronal plasticity induced by amphetamines. As a research scientist for 19 years, Andrea participated in academic projects in multiple research fields, from stroke, gene regulation, cancer, and rare diseases. She authored multiple research papers in peer-reviewed journals. She shifted towards a career in science writing and communication in 2022.

Articles by Andrea Lobo

Insecticide Impairs Gastrointestinal Function, May Increase Disease Risk

Being exposed to insecticides impacts gastrointestinal function and might increase the risk of developing Parkinson’s disease, a new study in mice shows. The research also shows exposure to a specific insecticide disrupts dopaminergic brain circuitries, and leads to motor deficits associated with Parkinson’s. When it comes to neurological disorders,…

Amneal’s Extended-release Carbidopa/Levodopa to Get Review

The U.S. Food and Drug Administration (FDA) will review Amneal Pharmaceuticals’ application for IPX203, its extended-release carbidopa/levodopa (CD/LD) tablet for Parkinson’s disease. Results from the Phase 3 RISE-PD clinical trial (NCT03670953) showed IPX203 can control Parkinson’s symptoms safely and effectively for longer periods with less frequent dosing,…

Neurotherapeutic Program Aims to Improve Motor, Cognitive Functions

MindMaze is partnering with Mount Sinai Health System in New York to accelerate the access of people with neurological diseases to a pioneer digital neurotherapeutic program to improve patients’ motor and cognitive functions. The program aims to provide high-dose and high-intensity training to improve the brain’s ability…

Aggression Aimed at Caregivers in Parkinson’s Linked to Patients’ Grief

Aggression aimed at caregivers in Parkinson’s disease and related disorders is associated with patients’ grief in coping with disease progression and related losses, a new study suggests. Fluctuations in cognition also play a role, researchers say. But these behavioral disturbances have serious consequences for caregivers, according to investigators, who…

Phase 2 Trial Supports DopaFuse for Levodopa-carbidopa Oral Delivery

Treatment with DopaFuse, a continuous oral levodopa-carbidopa delivery system being developed by SynAgile, was safe and lessened motor complications in people with Parkinson’s disease, according to results from a Phase 2 clinical trial. “These results suggest that the DopaFuse [levodopa-carbidopa] delivery system can provide a safe, non-invasive…

Dental Care Often Irregular But Needed With Parkinson’s: Study

Dental care often is irregular in people with Parkinson’s disease, who also require more dental treatments that those without this disease, a study from Denmark reported. High-quality initiatives addressing basic care, from daily oral cleanings to regular checkups that could reduce cavities and tooth extractions, are needed for better…

COVID-19 Might Increase Risk for Neurodegenerative Disease

People who had COVID-19 might have an increased risk for developing neurodegenerative diseases, such as Parkinson’s disease, researchers in Australia found. Moreover, the researchers have offered a possible treatment to reduce the  COVID-induced neuroinflammation. COVID-19 activates an inflammatory response in the brain that is similar to Parkinson’s disease, contributing…

Research Targets Neural Implants to Treat Brain Disorders

Neural implants combining artificial intelligence with microelectronics could directly modulate the brain’s activity to help treat brain disorders, including Parkinson’s disease. “Neurons talk to each other in part via electrical signals, and a therapeutic neural implant produces electrical stimulation – like a pacemaker for the brain. In cases of…

NYU Langone Health Joins Parkinson’s Progression Initiative

New York University Langone Health is collaborating with the Michael J. Fox Foundation for Parkinson’s Research in the Parkinson’s Progression Markers Initiative, a research program aiming to contribute to disease diagnosis and treatment. Launched in 2010 by the Michael J. Fox Foundation and a group of academic researchers…